IOL Chemicals & Pharmaceuticals Ltd
IOL Chemicals & Pharmaceuticals Q3 FY25 earnings call: Revenue & Margins
Q3 FY25 earnings call: what management guided on revenue, margins and order book.
The short version
The company anticipates a topline (sales/revenue) growth of around 10% to 12% for FY26 despite current market challenges. Expect topline growth of around 10% to 12% considering current scenario (Abhay Raj Singh).
From IOL Chemicals & Pharmaceuticals Ltd's Q3 FY25 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- The company anticipates a topline (sales/revenue) growth of around 10% to 12% for FY26 despite current market challenges.
- Demand and pricing in pharma and chemical sectors are expected to improve starting FY26, aiding growth.
- Chemical sector experts and company management expect recovery in chemical and API segments beginning Q2 onwards.
- There is focus on increasing exports, especially to Europe and Latin America, targeting 40%-45% export share in the coming years.
- Capacity utilization is aimed to increase from current ~75% towards 90% in the near term, enhancing volumes.
- New product approvals and market expansions, including REACH certification and entry into European markets, are key growth drivers.
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what IOL Chemicals & Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- The company has made capital expenditures (CAPEX) of Rs. 54 crore in Q3 FY25, lower than Rs. 80 crore in Q3 FY24 and Rs. 83 crore in Q2 FY25.
- Recent CAPEX includes starting acetic anhydride and other products, revamping the cogeneration plant, and environmental equipment including Effluent Treatment Plant (ETP).
- A new land was acquired on Chandigarh-Bhatinda Highway for setting up new facilities with a mix of chemicals and API plants; specific products are being finalized.
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on capex
Pro opens every point from 15K+ earnings calls
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what IOL Chemicals & Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
2 more points from IOL Chemicals & Pharmaceuticals Ltd's call on order book
Pro opens every point from 15K+ earnings calls
IOL Chemicals & Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹619 Cr, net profit ₹53 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What IOL Chemicals's management said in earlier quarters
- Q1 FY27 earnings call analysis →
- Q1 FY27 earnings call analysis →
- Q2 FY26 earnings call analysis →
- Q3 FY26 earnings call analysis →
- Q1 FY26 earnings call →
- Q4 FY25 earnings call →
- Q2 FY25 earnings call →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call →
- Q3 FY24 earnings call →
- Q2 FY24 earnings call →
- Q1 FY24 earnings call →
Others in Pharmaceuticals & Biotechnology this season
- SMS Pharma. (Q3 FY25)
Q3FY25 revenue from operations: ₹173.35 crore, up 7% YoY from ₹161.48 crore in Q3FY24 (Page 18, 5). Key concall takeaways from SMS Pharmaceuticals Ltd's Q3…
- Wockhardt Ltd (Q3 FY25)
725 crore, up 2% quarter-on-quarter and 2.2% year-on-year (Q3 FY24 revenue: Rs. Key concall takeaways from Wockhardt Ltd's Q3 FY25 earnings call — and how it…
- Shree Ganesh Rem (Q3 FY25)
Q3FY25 Revenue from Operations:** ₹27.05 Cr . Key concall takeaways from Shree Ganesh Remedies Ltd's Q3 FY25 earnings call — and how it ranks against sector…
- Themis Medicare (Q3 FY25)
93.81 Cr, a 13.69% year-on-year (YoY) increase from Rs. Key concall takeaways from Themis Medicare Ltd's Q3 FY25 earnings call — and how it ranks against…
Arthneeti Pro · Annual
IOL Chemicals & Pharmaceuticals Ltd and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were IOL Chemicals & Pharmaceuticals Ltd Q3 FY25 results?
The company anticipates a topline (sales/revenue) growth of around 10% to 12% for FY26 despite current market challenges. Expect topline growth of around 10% to 12% considering current scenario (Abhay Raj Singh).
What is IOL Chemicals & Pharmaceuticals Ltd share price analysis?
IOL Chemicals & Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 32.8 with a market cap of ₹4,797 Cr. Investors should review the full earnings analysis for detailed insights.
Is IOL Chemicals & Pharmaceuticals Ltd planning capital expenditure?
The company has made capital expenditures (CAPEX) of Rs.
Keep IOL Chemicals & Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.